Targeted therapy in antiphospholipid syndrome

Current Opinion in Rheumatology

Volumn 26, Issue 3, 2014, Pages 269-275

  Sciascia, Savino ^a,b   Khamashta, Munther A ^a,c   D'Cruz, David P ^c  

^a Graham Hughes Lupus Research Laboratory Lupus Research Unit Division of Women's Health   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

^c ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

antiphospholipid antibodies; antiphospholipid syndrome; novel therapy; pregnancy loss; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 10A INHIBITOR; CD20 ANTIBODY; COMPLEMENT; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B; IMMUNOGLOBULIN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHOLIPID ANTIBODY; RITUXIMAB; THROMBIN INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; CD20 ANTIGEN; IMMUNOLOGIC FACTOR;

ANTIPHOSPHOLIPID SYNDROME; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CELL ACTIVATION; COMPLEMENT INHIBITION; DRUG TARGETING; FOLLOW UP; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TARGET CELL; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIGENS, CD20; ANTIPHOSPHOLIPID SYNDROME; HUMANS; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; MOLECULAR TARGETED THERAPY;

EID: 84897479848     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000051     Document Type: Review

References (81)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306.
2. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993-997.
3. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376:1498-1509.
4. Arachchillage DJ, Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 2013; 15:331.
5. Pericleous C, Ioannou Y. New therapeutic targets for the antiphospholipid syndrome. Expert Opin Ther Targets 2010; 14:1291-1299.
6. Pierangeli SS, Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus 2010; 19:475-485.
7. Pradaxa 150 mg hard capsules: summary of product characteristics (SPC), EU. Boehringer Ingelheim International GmBH. www.emc.medicines.org.uk. [Accessed 21 September 2012]
8. Xarelto 10 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bayer HealthCare AG. Date of first authorisation/renewal of authorisation: 30/09/08. Date of revision 12/2011. www.emc.medicines.org.uk. [Accessed 5 January 2014]
9. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
10. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883-891.
11. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency 26/07/2012 Pradaxa-EMEA/H/C/000829-II/0032.
12. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. 09/12/2011 Xarelto-EMEA/H/C/000944-X/0010.
13. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
14. Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112:2242-2247.
15. Giles I, Khamashta M, D'Cruz D, Cohen H. A new dawn of anticoagulation for patients with antiphospholipid syndrome? Lupus 2012; 21:1263-1265.
16. Edwards MH, Pierangeli S, Liu X, et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96:4380-4384.
17. Fangtham M, Petri M. 2013 update: Hopkins lupus cohort. Curr Rheumatol Rep 2013; 15:360.
18. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993; 2 (Suppl 1):S13-S15.
19. Ho KT, Ahn CW, Alarcon GS, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005; 44:1303-1307.
20. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112:1687-1695.
21. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010; 115: 2292-2299.
22. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61:29-36.
23. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multiethnic cohort. Ann Rheum Dis 2009; 68:238-241.
24. Albert CR, Schlesinger WJ, Viall CA. Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function. Am J Reprod Immunol 2014; 71:154-164.
25. Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients, IRSCTN NCT01784523.
26. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48:3272-3279.
27. Meroni PL, Raschi E, Testoni C, et al. Statins prevent endothelial cell activation induced by antiphospholipid (antibeta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44:2870-2878.
28. Merwick A, Albers GW, Arsava EM, et al. Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment. Stroke 2013; 44:2814-2820.
29. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010; 340:c2197.
30. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360:1851-1861.
31. Pierangeli SS, Ferrara DE. More on: fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2005; 3:1112-1113.
32. Ferrara DE, Swerlick R, Casper K, et al. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004; 2:1558-1563.
33. Girardi G. Pravastatin prevents miscarriages in antiphospholipid antibodytreated mice. J Reprod Immunol 2009; 82:126-131.
34. Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 2011; 70:675-682.
35. Sivapalaratnam S, Basart H, Watkins NA, et al. Monocyte gene expression signature of patients with early onset coronary artery disease. PLoS One 2012; 7:e32166.
36. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45:89-118.
37. Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, et al. Potential use of statins in the treatment of antiphospholipid syndrome. Curr Rheumatol Rep 2012; 14:87-94.
38. Lockshin MD, Pierangeli SS. Statins for the treatment of obstetric complications in antiphospholipid syndrome? J Reprod Immunol 2010; 84:206.
39. Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients. ClinicalTrials.gov [Accessed 5 January 2014]. Identifier: NCT00674297.
40. Jajoria P, Murthy V, Papalardo E, et al. Statins for the treatment of antiphospholipid syndrome? Ann N Y Acad Sci 2009; 1173:736-745.
41. Odiari EA, Mulla MJ, Sfakianaki AK, et al. Pravastatin does not prevent antiphospholipid antibody-mediated changes in human first trimester trophoblast function. Hum Reprod 2012; 27:2933-2940.
42. Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med 2011; 22:220-229.
43. Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008; 17:50-55.
44. Bakshi J, Stevens R. Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome. Lupus 2013; 22:865-867.
45. Berman H, Rodriguez-Pinto I, Cervera R, et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013; 12:1085-1090.
46. Sciascia S, Naretto C, Rossi D, et al. Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus 2011; 20:1106-1108.
47. Erkan D, Vega J, Ramon G, et al. A pilot open-label phase II trial of rituximab for noncriteria manifestations of antiphospholipid syndrome. Arthritis Rheum 2013; 65:464-471.
48. Boles J, Mackman N. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus 2010; 19:370-378.
49. Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104:2353-2358.
50. Holy EW, Tanner FC. Tissue factor in cardiovascular disease pathophysiology and pharmacological intervention. Adv Pharmacol 2010; 59:259-292.
51. Morrow DA, Murphy SA, McCabe CH, et al. Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial. Eur Heart J 2005; 26:682-688.
52. Kubota T, Fukuya Y, Hashimoto R, et al. Possible involvement of chemokineinduced platelet activation in thrombophilic diathesis of antiphospholipid syndrome. Ann N Y Acad Sci 2009; 1173:137-145.
53. Vega-Ostertag ME, Ferrara DE, Romay-Penabad Z, et al. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost 2007; 5: 1828-1834.
54. Branger J, van den Blink B, Weijer S, et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 2003; 101:4446-4448.
55. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009; 60:1232-1241.
56. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682-687.
57. Redecha P, Tilley R, Tencati M, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 2007; 110:2423-2431.
58. Girardi G. Guilty as charged: all available evidence implicates complement's role in fetal demise. Am J Reprod Immunol 2008; 59:183-192.
59. Pierangeli SS, Vega-Ostertag M, Liu X, Girardi G. Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome. Ann N Y Acad Sci 2005; 1051:413-420.
60. Carrera-Marin AL R-PZ, Qu HC, et al. A C5a receptor antagonist ameliorates in vivo effects of antiphospholipidantibodies. Arthritis Rheum 2009; 60:s767.
61. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014; 14:459-465.
62. Espinosa G, Berman H, Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011; 10:664-668.
63. Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 362:1744-1745.
64. Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) (PROMISSE) Accession date 05/01/2014. ClinicalTrials.gov Identifier: NCT00198068.
65. Salmon JE, Girardi G, Theodore E. Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation. Trans Am Clin Climatol Assoc 2007; 118:99-114.
66. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood 2009; 114:3074-3083.
67. Zhang J, McCrae KR. Annexin A2 mediates endothelial cell activation by antiphospholipid/antibeta2 glycoprotein I antibodies. Blood 2005; 105: 1964-1969.
68. Ostertag MV, Liu X, Henderson V, Pierangeli SS. A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus 2006; 15:358-365.
69. Ioannou Y, Pericleous C, Giles I, et al. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007; 56:280-290.
70. De Laat B, Derksen RH, Urbanus RT, De Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105:1540-1545.
71. Iverson GM, Victoria EJ, Marquis DM. Antibeta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci USA 1998; 95:15542-15546.
72. Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost 2009; 7:833-842.
73. Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. J Autoimmun 2009; 33:92-98.
74. Branch DW, Peaceman AM, Druzin M, et al., The Pregnancy Loss Study Group. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 2000; 182:122-127.
75. Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum 2003; 48:728-731.
76. Sciascia S, Giachino O, Roccatello D. Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol 2012; 30:409-413.
77. Tenti S, Guidelli GM, Bellisai F, et al. Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy. Clin Exp Rheumatol 2013; 31:877-882.
78. Tyndall A. Successes and failures of stem cell transplantation in autoimmune diseases. Hematol Am Soc Hematol Educ Program 2011; 2011:280-284.
79. Statkute L, Traynor A, Oyama Y, et al. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood 2005; 106:2700-2709.
80. Owaidah TM, Maghrabi K, Elkarouri MA, et al. Successful treatment of a case of catastrophic antiphospholipid syndrome with autologous BMT: case report and review of literature. Bone Marrow Transplant 2011; 46:597-600.
81. Hashimoto N, Iwasaki T, Sekiguchi M, et al. Autologous hematopoietic stem cell transplantation for refractory antiphospholipid syndrome causing myocardial necrosis. Bone Marrow Transplantat 2004; 33:863-866.